ADVANCES IN THERAPY
ADV THER
影响因子:3.4
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:ENGLAND
出版社:Springer Healthcare
发刊时间:2000
发刊频率:Monthly
收录数据库:SCIE/Scopus收录
ISSN:0741-238X

中科院2-4区医学SCI协投:

影响因子0-3分,2-4个月确保录用

医学全方向沾边就收,无需大修

微信扫码提交文章

期刊介绍
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
《治疗进展》是一本国际性、同行评审、快速出版(2周内完成同行评审,接受后3-4周内出版)期刊,致力于出版高质量的临床(所有阶段)、观察性、真实世界和健康结局研究,这些研究围绕所有治疗领域的治疗和干预(包括器械)的发现、开发和使用。同时,也鼓励与诊断学、药物经济学、公共卫生、流行病学、生活质量、患者护理、管理和教育相关的研究。该杂志是广大医疗保健专业人士感兴趣的杂志,发表原创研究、评论、通信和信件。该杂志面向全球读者,并收到来自世界各地的投稿。《治疗进展》将考虑所有科学上合理的研究,无论是阳性、确证性或阴性数据。无论是针对国际和/或特定国家的受众,我们都欢迎提交材料,当研究人员试图针对更特定的患者人群时,这一点至关重要。这种包容性的方法使该杂志能够协助传播所有科学和道德上健全的研究。
年发文量 321
国人发稿量 22.47
国人发文占比 0.07%
自引率 -
平均录取率0
平均审稿周期 较慢,6-12周
版面费 US$4190
偏重研究方向 医学-药学
期刊官网 https://www.springer.com/12325/?utm_medium=display&utm_source=letpub&utm_content=text_link&utm_term=null&utm_campaign=MLSR_12325_AWA1_CN_CNPL_letpb_mp
投稿链接 https://www.editorialmanager.com/adth
期刊高被引文献
Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00981-y
Analgesic Efficacy, Practicality and Safety of Inhaled Methoxyflurane Versus Standard Analgesic Treatment for Acute Trauma Pain in the Emergency Setting: A Randomised, Open-Label, Active-Controlled, Multicentre Trial in Italy (MEDITA)
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01055-9
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0895-1
Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01008-2
Case Series of Combined iStent Implantation and Phacoemulsification in Eyes with Primary Angle Closure Disease: One-Year Outcomes
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00899-5
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01015-3
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
来源期刊:Advances in TherapyDOI:10.1007/s12325-018-0868-9
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00908-7
Clinical Application of LC–MS/MS in the Follow-Up for Treatment of Children with Methylmalonic Aciduria
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00955-0
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01017-1
Management of Fibrosing Interstitial Lung Diseases
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00992-9
Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00906-9
Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00956-z
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01145-8
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01157-4
Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0887-1
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00965-y
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01124-z
Liaoning Score for Prediction of Esophageal Varices in Cirrhotic Patients Who Had Never Undergone Endoscopy: A Multicenter Cross-Sectional Study in Liaoning Province, China
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00967-w
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01018-0
Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01036-y
Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00976-9
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00907-8
Understanding the Patient Perception of Statin Experience: A Qualitative Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01073-7
Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01075-5
Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00974-x
Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01058-6
The Association Between Type 2 Diabetes and Cardiovascular Disease: The “For Your SweetHeart™” Survey
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0871-9
Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0894-2
Factors Determining the Choice of Spinal Versus General Anesthesia in Patients Undergoing Ambulatory Surgery: Results of a Multicenter Observational Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01171-6
Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0890-6
Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01112-3
Surgery for Idiopathic Epimacular Membrane: Morpho-Functional Outcomes Based on the Preoperative Macular Integrity of the Photoreceptoral Junction. A Prospective Pilot Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01165-4
Impact of Chloroprocaine on the Eligibility for Hospital Discharge in Patients Requiring Ambulatory Surgery Under Spinal Anesthesia: An Observational Multicenter Prospective Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01172-5
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01032-2
The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00935-4
Reporting Clinical Trial Results of Phytomedicines in Acute Rhinosinusitis: Letter to the Editor Regarding Gottschlich S, Röschmann K, Candler H. Adv Ther (2018); 35:1023–1034. doi: 10.1007/s12325-018-0736-7
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00933-6
Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00910-z
Recognising Skin Cancer in Primary Care
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01130-1
Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01161-8
Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE1): A Study Protocol of a Non-Interventional Registry Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00987-6
Correction to: Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0892-4
Response Letter Addressing Letter to the Editor Regarding Gottschlich S, Röschmann K, Candler H. Adv Ther (2018); 35:1023–1034. doi:10.1007/s12325-018-0736-7
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00934-5
Methylmalonic Acidemia Complicated by Homocystinuria Diseases: a Report of Three Cases
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01149-4
Stepwise Decreasing of Vitreous Pressure by Anterior Vitrectomy: A Novel Method for Preventing Positive Vitreous Pressure During Penetrating Keratoplasty
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01139-6
Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01195-y
COPD Exacerbations: A Patient and Physician’s Perspective
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01138-7
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-00993-8
Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-0888-0
Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
来源期刊:Advances in TherapyDOI:10.1007/s12325-019-01082-6
质量指标占比
研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
78.82%77.17%-4.71%
相关指数
影响因子
影响因子
年发文量
自引率
Cite Score
预警情况 查看说明
时间 预警情况
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2021年01月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》
JCR分区 WOS分区等级:Q2区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2022-2023年最新版)
PHARMACOLOGY & PHARMACY
Q2
MEDICINE, RESEARCH & EXPERIMENTAL
Q3
中科院分区 查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2023年12月最新升级版
医学3区
PHARMACOLOGY & PHARMACY
药学
3区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
3区
2022年12月升级版
医学3区
PHARMACOLOGY & PHARMACY
药学
3区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
3区
2021年12月基础版
医学3区
PHARMACOLOGY & PHARMACY
药学
3区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
4区
2021年12月升级版
医学3区
PHARMACOLOGY & PHARMACY
药学
3区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
3区
2020年12月旧升级版
医学3区
PHARMACOLOGY & PHARMACY
药学
3区
MEDICINE, RESEARCH & EXPERIMENTAL
医学:研究与实验
3区